Snowball logo
logo
LIAN

LianBio

$0.06$0.00  (0%)
Estimate
EPS
-0.28
Beta
0.102
About the company
Ticker
LIANY
ISIN
US53000N1081
Country
United States of America
Sector (GICS)
Healthcare
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was formerly known as LianBio and changed its name to LianMedical in July 2026. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Frequently asked questions

What sector does LianBio (LIANY) operate in?

LianBio belongs to the Healthcare sector and operates in the Biotechnology industry.

What is LianBio (LIANY) current stock price?

As of the latest data, LianBio stock price is $0.06, with a previous close of $0.06.

What is LianBio (LIANY) current market capitalization?

LianBio market cap is approximately 6.55 million.

What is LianBio (LIANY) Earnings Per Share (EPS)?

The trailing EPS is -$0.28.

Does LianBio (LIANY) pay dividends?

No. LianBio does not pay a dividend.

What is LianBio (LIANY) beta (volatility) score?

LianBio has a beta of 0.102, indicating lower volatility than the overall market.